MedTrace Logo

Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00021164 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-19

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells.

PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer.

Conditions

  • Melanoma (Skin)
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

telomerase: 540-548 peptide vaccine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Steven A. Rosenberg, MD, PhD · NCI - Surgery Branch

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Completion
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00021164 on ClinicalTrials.gov